Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has seen a decline in its stock price by -2.84 in relation to its previous close of 10.90. However, the company has experienced a -5.11% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-12 that – 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). The data are being presented in posters at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually.
Is It Worth Investing in Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Right Now?
Moreover, the 36-month beta value for SNDX is 0.75. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNDX is 82.47M and currently, short sellers hold a 28.06% of that float. On June 12, 2025, SNDX’s average trading volume was 2.15M shares.
SNDX’s Market Performance
SNDX stock saw an increase of -5.11% in the past week, with a monthly gain of 3.93% and a quarterly increase of -19.16%. The volatility ratio for the week is 2.98%, and the volatility levels for the last 30 days are 4.84% for Syndax Pharmaceuticals Inc (SNDX). The simple moving average for the last 20 days is 0.88% for SNDX stock, with a simple moving average of -29.32% for the last 200 days.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with UBS repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to UBS is $37 based on the research report published on October 24, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $37. The rating they have provided for SNDX stocks is “Buy” according to the report published on June 28th, 2024.
Scotiabank gave a rating of “Sector Perform” to SNDX, setting the target price at $23 in the report published on January 31st of the previous year.
SNDX Trading at -6.49% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.76% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Botwood Nicholas A.J., who purchase 11,765 shares at the price of $8.99 back on May 16 ’25. After this action, Botwood Nicholas A.J. now owns 35,165 shares of Syndax Pharmaceuticals Inc, valued at $105,826 using the latest closing price.
Huber Martin H. Jr., the Director of Syndax Pharmaceuticals Inc, purchase 5,000 shares at $8.99 during a trade that took place back on May 19 ’25, which means that Huber Martin H. Jr. is holding 79,000 shares at $44,950 based on the most recent closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -7.87 for the present operating margin
- -0.03 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -7.58. The total capital return value is set at -0.63. Equity return is now at value -93.70, with -55.96 for asset returns.
Currently, EBITDA for the company is -313.82 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 17.18. The receivables turnover for the company is 2.78for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.80.
Conclusion
To wrap up, the performance of Syndax Pharmaceuticals Inc (SNDX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
